Intuitive Surgical maintains a dominant, near-monopoly position in soft-tissue robotic surgery. Its massive installed base of da Vinci systems creates a razor-and-blade model with high switching costs, generating robust recurring revenues from instruments and accessories. Strong free cash flow generation and high ROIC solidify its status as a premier quality compounder. Fair value range: low $176, high $337, with mid-point at $255.
Stock analysis
Intuitive Surgical Inc.ISRG Intuitive Surgical Inc. fair value $255–$337
لم تتم ترجمة هذا التقرير بعد. قم بالتحديث خلال بضع دقائق بمجرد أن تلحق قائمة انتظار الترجمة بالركب.
§1 الملخص التنفيذي
Premium quality compounder with a wide competitive moat.
Reverse DCF implies ~20% perpetual growth required at current $450 price.
Intrinsic valuation models anchor at $254.67, signaling a massive premium.
Sell recommendation driven by extreme valuation disconnect, not business quality.
Fair value
$255
Margin of safety
-76.7%
Confidence
87/100
Moat
9/10
Educational analysis only — not financial advice. Always do your own due diligence.
$450.06Price
FV $254.67
High $336.56
Intuitive Surgical maintains a dominant, near-monopoly position in soft-tissue robotic surgery. Its massive installed base of da Vinci systems creates a razor-and-blade model with high switching costs, generating robust recurring revenues from instruments and accessories. Strong free cash flow generation and high ROIC solidify its status as a premier quality compounder.
Massive installed base of da
Massive installed base of da Vinci systems
High switching costs for hospitals
High switching costs for hospitals and surgeons
Cycle upside
Post-pandemic procedure backlog clearance drives elevated system utilization and instrument consumption.
Based on our latest independent analysis, ISRG looks meaningfully overvalued. The current price is $450 versus a composite fair-value midpoint of $255 (range $176–$337), which implies roughly 43.4% downside to the midpoint.
Our composite fair-value range for ISRG is $176–$337, with a midpoint of $255. The range is triangulated across multiple valuation models (discounted earnings, forward earnings scenarios, peer multiples, and where applicable owner earnings or reverse DCF) and weighted by reliability for Intuitive Surgical Inc.'s archetype.
Our current rating for ISRG is Sell with a confidence score of 87/100. Sell. The 56% divergence from consensus target signals heavy market premium; intrinsic baseline valuation is $254.67. This is independent research for educational purposes, not personalized investment advice.
The top risks our latest report flags for Intuitive Surgical Inc. are: Medtronic/J&J Capture 30% Market Share; Severe Hospital Capex Freeze; New Modality Disruption. The single biggest risk is Medtronic/J&J Capture 30% Market Share: Competitors successfully disrupt the monopoly, forcing severe pricing pressure on systems and instruments.
Our current rating for ISRG is Sell, issued with a confidence score of 87/100 and a moat score of 9/10. The rating reflects the composite fair-value range ($176–$337) versus the current price of $450.
Intuitive Surgical Inc. is classified as a mature compounder stock. Archetype determines how every downstream parameter — discount rate, terminal growth, deceleration curve, terminal multiple, scenario probability weights, scorecard weights, and which valuation models are prioritized — is calibrated for ISRG.
